Astrana Health Files 8-K/A Amendment
Ticker: ASTH · Form: 8-K/A · Filed: Sep 11, 2025 · CIK: 1083446
Sentiment: neutral
Topics: amendment, 8-K
TL;DR
Astrana Health (APLS) filed an 8-K/A amendment, check for updates on July 1st event.
AI Summary
Astrana Health, Inc. filed an 8-K/A amendment on September 11, 2025, related to an event on July 1, 2025. The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, formerly known as Apollo Medical Holdings, Inc., is incorporated in Delaware and headquartered in Alhambra, California.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be material for investors.
Risk Assessment
Risk Level: low — This is a routine amendment filing without immediate financial implications disclosed.
Key Players & Entities
- Astrana Health, Inc. (company) — Registrant
- Apollo Medical Holdings, Inc. (company) — Former Company Name
- July 1, 2025 (date) — Earliest event date
- September 11, 2025 (date) — Filing Date
- 1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801 (address) — Principal Executive Offices
FAQ
What is the purpose of this 8-K/A filing?
This is an amendment to a previous current report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the exact name of the registrant?
The exact name of the registrant is Astrana Health, Inc.
When was the earliest event reported in this filing?
The earliest event reported was on July 1, 2025.
What was Astrana Health, Inc. formerly known as?
Astrana Health, Inc. was formerly known as Apollo Medical Holdings, Inc.
Where are Astrana Health, Inc.'s principal executive offices located?
Astrana Health, Inc.'s principal executive offices are located at 1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801.
Filing Stats: 1,002 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2025-09-11 07:20:00
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ASTH The Nasdaq
Filing Documents
- tm2525148d1_8ka.htm (8-K/A) — 31KB
- tm2525148d1_ex23-1.htm (EX-23.1) — 2KB
- tm2525148d1_ex99-1.htm (EX-99.1) — 719KB
- tm2525148d1_ex99-2.htm (EX-99.2) — 517KB
- tm2525148d1_ex99-3.htm (EX-99.3) — 879KB
- tm2525148d1_ex99-1img01.jpg (GRAPHIC) — 225KB
- tm2525148d1_ex99-1img02.jpg (GRAPHIC) — 8KB
- tm2525148d1_ex99-2sp1img001.jpg (GRAPHIC) — 8KB
- 0001104659-25-089230.txt ( ) — 2844KB
- asth-20250701.xsd (EX-101.SCH) — 3KB
- asth-20250701_lab.xml (EX-101.LAB) — 33KB
- asth-20250701_pre.xml (EX-101.PRE) — 22KB
- tm2525148d1_8ka_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Business Acquired. The audited financial statements of the Acquired Business as of and for the fiscal years ended September 30, 2024 and 2023, and the related Report of Independent Auditors, and the unaudited financial statements of the Acquired Business as of and for the six months ended March 31, 2025 and for the six months ended March 31, 2024, including, in each case, the accompanying notes, are filed as Exhibit 99.1 and Exhibit 99.2 , respectively, to this Current Report on Form 8-K/A and are incorporated herein by reference. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined balance sheet of the Company as of March 31, 2025 and the unaudited pro forma condensed combined statements of operations of the Company for the fiscal year ended December 31, 2024 and for the three months ended March 31, 2025 (collectively, the "Unaudited Pro Forma Financial Information") are filed as Exhibit 99.3 to this Current Report on Form 8-K/A and are incorporated herein by reference. The Unaudited Pro Forma Financial Statements give effect to the Transaction and related transactions. The Unaudited Pro Forma Financial Information is presented for illustrative purposes only and is not intended to represent or be indicative of the Company's consolidated results of operations or financial position that would have been reported had the Transaction and related transactions been completed as of the dates presented in the Unaudited Pro Forma Financial Information. The Unaudited Pro Forma Financial Information should not be taken as a representation of the Company's future consolidated results of operations or financial condition. The pro forma adjustments in the Unaudited Pro Forma Financial Information are based on available information and certain assumptions that management believes are reasonable under the circumstances. (d) Exhibits. Exhibit No. Description 23.1 Co
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASTRANA HEALTH, INC. Date: September 11, 2025 By: /s/ Brandon K. Sim Name: Brandon K. Sim Title: Chief Executive Officer and President